West Pharmaceutical Services (NYSE:WST) Updates FY 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 8.850-9.050 for the period, compared to the consensus estimate of 8.610. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion. West Pharmaceutical Services also updated its Q3 2026 guidance to 2.140-2.240 EPS.

West Pharmaceutical Services Stock Down 7.6%

Shares of NYSE WST opened at $328.61 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $23.22 billion, a PE ratio of 42.08, a P/E/G ratio of 2.77 and a beta of 1.16. The company’s fifty day simple moving average is $337.02 and its 200 day simple moving average is $287.43. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the firm posted $1.84 earnings per share. The business’s revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services will post 8.95 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

Wall Street Analysts Forecast Growth

WST has been the subject of several research reports. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Wolfe Research initiated coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. Evercore reaffirmed an “outperform” rating and set a $410.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 6th. Morgan Stanley raised their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $363.17.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company’s stock.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
• Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
• Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
• Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

Institutional Trading of West Pharmaceutical Services

Hedge funds have recently made changes to their positions in the company. CYBER HORNET ETFs LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at $25,000. DV Equities LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth about $28,000. MUFG Securities EMEA plc bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $47,000. State of Wyoming purchased a new stake in West Pharmaceutical Services during the second quarter valued at about $49,000. Finally, Meeder Asset Management Inc. lifted its holdings in West Pharmaceutical Services by 1,023.5% during the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 174 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.